You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
TRKing Down an Old Oncogene in a New Era of Targeted Therapy
|
|---|---|
| Published in |
Cancer Discovery, January 2015
|
| DOI | 10.1158/2159-8290.cd-14-0765 |
| Pubmed ID | |
| Authors |
Aria Vaishnavi, Anh T Le, Robert C Doebele |
| Abstract |
The use of high-throughput next-generation sequencing techniques in multiple tumor types during the last few years has identified NTRK1, 2, and 3 gene rearrangements encoding novel oncogenic fusions in 19 different tumor types to date. These recent developments have led us to revisit an old oncogene, Trk (originally identified as OncD), which encodes the TPM3-NTRK1 gene fusion and was one of the first transforming chromosomal rearrangements identified 32 years ago. However, no drug has yet been approved by the FDA for cancers harboring this oncogene. This review will discuss the biology of the TRK family of receptors, their role in human cancer, the types of oncogenic alterations, and drugs that are currently in development for this family of oncogene targets. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 50% |
| Spain | 1 | 25% |
| Unknown | 1 | 25% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 3 | 75% |
| Practitioners (doctors, other healthcare professionals) | 1 | 25% |
Mendeley readers
The data shown below were compiled from readership statistics for 289 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Germany | 1 | <1% |
| Netherlands | 1 | <1% |
| France | 1 | <1% |
| United Kingdom | 1 | <1% |
| United States | 1 | <1% |
| Unknown | 284 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 56 | 19% |
| Student > Ph. D. Student | 33 | 11% |
| Student > Master | 27 | 9% |
| Other | 24 | 8% |
| Student > Bachelor | 23 | 8% |
| Other | 35 | 12% |
| Unknown | 91 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 71 | 25% |
| Biochemistry, Genetics and Molecular Biology | 45 | 16% |
| Agricultural and Biological Sciences | 30 | 10% |
| Neuroscience | 10 | 3% |
| Pharmacology, Toxicology and Pharmaceutical Science | 10 | 3% |
| Other | 22 | 8% |
| Unknown | 101 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 70. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 April 2024.
All research outputs
#621,897
of 26,017,215 outputs
Outputs from Cancer Discovery
#332
of 4,151 outputs
Outputs of similar age
#7,673
of 364,223 outputs
Outputs of similar age from Cancer Discovery
#4
of 67 outputs
Altmetric has tracked 26,017,215 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,151 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 22.2. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 364,223 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 67 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.